1. An assembly comprising:
an internal shaft and an external shaft, said internal and external shafts being coaxial and a forward part of the internal shaft projecting beyond a forward end of the external shaft;
a sleeve surrounding the shafts and holding first and second seals, the first seal sealing a portion of the internal shaft and the second seal sealing a portion of the external shaft;
a first bearing supporting the forward end of the external shaft;
a nut screwed around said forward end for providing a stop for said first bearing; and
a spacer having a first part adjusted around the external shaft and retained between the nut and the first bearing, and a second part extending around the nut on which the second seal sealing with the external shaft rubs.
2. (canceled)
3. The assembly according to claim 1, further comprising:
a gear arranged under the nut, the spacer and the sleeve in a direction substantially perpendicular to both shafts;
a gear support housing surrounding the gear; and
a gear hub holding the gear in said direction, wherein a second bearing for the gear is installed around a shaft of the gear by an ascending displacement from below the housing, and the sleeve comprises a flange in abutment with a part of the housing, the abutment being obtained by a forward displacement of the flange.
4. The assembly according to claim 3, further comprising:
a single shell fixed to the housing, in which the second bearing and a third bearing installed around the shaft of the gear are installed.
5. The assembly according to claim 1, wherein a diameter of the second seal is larger than a diameter of the first seal.
6. The assembly according to claim 1, wherein the sleeve is conical.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-31. (canceled)
32. A method comprising the following step:
(a) identifying an individual with Type 1 Diabetes (T1D) who will respond positively to injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of the individual,
wherein the pharmaceutical composition at least partially reverses recent onset Type 1 Diabetes (T1D) in the individual.
33. The method of claim 32, wherein the individual in step (a) is identified based on DNA in a saliva sample from the individual obtained using a DNA collection kit.
34. The method of claim 32, wherein the pharmaceutical composition completely reverses recent onset T1D.
35. The method of claim 32, wherein the pharmaceutical composition transiently for months to years reverses recent onset T1D.
36. The method of claim 32, wherein the pharmaceutical composition aids storage, production and release of insulin by beta cells in a pancreas.
37. The method of claim 32, wherein step (a) is conducted for at least three minutes.
38. The method of claim 32, wherein the pharmaceutical composition comprises a neuropeptide.
39. The method of claim 32, wherein the pharmaceutical composition comprises substance P.
40. The method of claim 39, wherein substance P is dissolved in saline in the pharmaceutical composition.
41. The method of claim 32, wherein the individual has recent onset of Type 1 Diabetes (T1D).
42. The method of claim 41, wherein the individual is diagnosed with T1D based on DNA from a saliva sample obtained using a DNA collection kit.
43. The method of claim 32, wherein the individual is a human.
44. The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is at least 10 nMkg.
45. The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is at least 50 nMkg.
46. The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is at least 100 nMkg.
47. The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is at least 250 nMkg.